Journal Mobile Options
Table of Contents
Vol. 43, No. 3, 1999
Issue release date: May–June 1999
Section title: Original Paper
Ann Nutr Metab 1999;43:173–180
(DOI:10.1159/000012783)

Cholesterol-Lowering Activity of Naringenin via Inhibition of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Acyl Coenzyme A:Cholesterol Acyltransferase in Rats

Lee S.H. · Park Y.B. · Bae K.H. · Bok H. · Kwon Y.K. · Lee E.S. · Choi M.S.
aDepartment of Nutrition and Food Science and bDepartment of Genetic Engineering, Kyungpook National University, Taegu, cChungnam National University School of Pharmacy, Taejon, and dKorea Institute of Bioscience and Biotechnology, KIST, Taejon, South Korea

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: 10/20/1999

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 3

ISSN: 0250-6807 (Print)
eISSN: 1421-9697 (Online)

For additional information: http://www.karger.com/ANM

Abstract

The effects of dietary supplementation of a citrus bioflavonoid, naringenin, on the cholesterol metabolism were studied. For 42 days male rats were fed a 1% (wt/wt) high-cholesterol diet with or without a naringenin supplementation (0.1%, wt/wt) to study its effect on plasma lipid levels, hepatic lipid contents, activities of hepatic acyl coenzyme A:cholesterol O-acyltransferase (ACAT) and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, and the excretion of fecal neutral sterols. Naringenin did not significantly alter the concentration of plasma triglycerides, but lowered the plasma cholesterol (3.80 vs. 3.12 mmol/l) concentration and the hepatic cholesterol content (70.3 vs. 54.0 mg/g) significantly (p < 0.05) compared to those of the controls. HMG-CoA reductase (1,879.0 vs. 1,715.0 pmol/min/mg) and ACAT activities (806.0 vs. 563.0 pmol/min/mg) were significantly lower in the naringenin-supplemented group than in controls. Naringenin supplementation caused a marked decrease in the excretion of fecal neutral sterols (242.9 mg/day) compared to the controls (521.9 mg/day). These results show that naringenin lowers the plasma and hepatic cholesterol concentrations by suppressing HMG-CoA reductase and ACAT in rats fed a high-cholesterol diet.


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: 10/20/1999

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 3

ISSN: 0250-6807 (Print)
eISSN: 1421-9697 (Online)

For additional information: http://www.karger.com/ANM


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Wald NJ, Law MR: Serum cholesterol and ischaemic heart disease. Atherosclerosis 1995;118(suppl):1–5.
  2. Alberts AW, Chen J, Kuron G, et al: Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 1980;77:3957–3961.
  3. Amin D, Gustafson SK, Weinacht JM, et al: RG 12561 (Dalvastatin): A novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent. Pharmacology 1993;46:13–22.
  4. Alberts W: Discovery, biochemistry and biology of lovastatin. Am J Cardiol 1988;62:10J–15J.
  5. Fujioka T, Nara F, Tsujita Y, et al: The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim Biophys Acta 1995;1254:7–12.
  6. Lovastatin Study Groups I through IV: Lovastatin 5-year safety and efficacy study. Arch Intern Med 1993;153:1079–1087.
  7. Brown MS, Ho YK, Goldstein JL: The cholesteryl ester cycle in macrophage foam cells. Continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters. J Biol Chem 1980;255:9344–9352.

    External Resources

  8. Kannel WB, Casteri WP, Gondon T, et al: Serum cholesterol, lipoproteins, and the risk of coronary heart disease: The Framingham Study. Ann Intern Med 1971;74:1–12.
  9. Frick MH, Elso O, Haapa K, et al: Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237–1245.
  10. Helgerud P, Sarem K, Kare R: Norum. Acyl-CoA:cholesterol acyltransferase in human small intestine: Its activity and some properties of the enzyme reaction. J Lipid Res 1981;22:271–277.
  11. Suckling KE, Stange EF: Role of acyl-CoA:cholesterol acyltransferase in cellular cholesterol metabolism. J Lipid Res 1985;26:647–659.
  12. Aboobaker VS, Balgi AD, Bhattacharya RK: In vivo effect of dietary factors on the molecular action of aflatoxin B1: Role of non-nutrient phenolic compounds on the catalytic activity of liver fraction. In Vivo 1994;8:1095–1098.

    External Resources

  13. Buening MK, Chang RL, Huang MT, et al: Activation and inhibition of benzo(a)pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res 1981;41:67–72.

    External Resources

  14. Hardigree AA, Epler JL: Comparative mutagenesis of plant flavonoids in microbial systems. Mutat Res 1978;58:231–239.
  15. Basarkar PW, Nath N: Cholesterol lowering action of vitamin P-like compounds in rats. Indian J Exp Biol 1981;19:787–789.

    External Resources

  16. Rathi AB, Nath N, Chari SN: Activation of vitamin P like compounds on lysosomal fragility in hypercholesterolemia: Implication of ascorbic acid and its metabolites. Acta Vitaminol Enzymol 1984;6:97–102.

    External Resources

  17. Monforte MT, Trovato A, Kirjavainen S, et al: Biological effects of hesperidin, a Citrus flavonoid (note II): Hypolipidemic activity on experimental hypercholesterolemia in rat. Farmaco 1995;50:595–599.
  18. American Institute of Nutrition: Report of the American Institute of Nutrition. Ad Hoc Committee of Standards for Nutritional Studies. J Nutr 1977;107:1340–1348.
  19. American Institute of Nutrition: Report of Ad Hoc Committee on Standards for Nutritional Studies. J Nutr 1980;110:1726.
  20. Allain CC, Poon LS, Chan CSG, et al: Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470–475.
  21. Warnick RG, Albers JJ: A comprehensive evaluation of the heparin-manganease precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 1978;19:65–76.
  22. McGowan MW, Artiss JD, Strandbergh DR, et al: A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 1983;29:538–542.
  23. Folch J, Lees M, Sloan-Stanley GH: A simple method for isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497–509.
  24. Omodeo Sale, Marchesini S, Fishman PH, et al: A sensitive enzymatic assay for determination of cholesterol in lipid extract. Anal Biochem 1984;142:347–350.
  25. Czubayko F, Beumers B, Lammsfuss S, et al: A simplified micro-method for quantification of fecal excretion of neutral and acidic sterols for outpatient studies in humans. J Lipid Res 1991;32:1861–1867.
  26. Hulcher FH, Oleson WH: Simplified spectrophotometric assay for microsomal 3-hydroxy-3-methylglutaryl CoA reductase by measurement of coenzyme A. J Lipid Res 1973;14:625–631.
  27. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.
  28. Shapiro DJ, Nordstrom JL, Mitschelen JJ, et al: Micro assay for 3-hydroxy-3-methylglutaryl-CoA reductase in rat liver and in L-cell fibroblasts. Biochim Biophys Acta 1974;370:369–377.
  29. Erickson SK, Schrewsbery MA, Brooks C, et al: Rat liver acyl-coenzyme A: cholesterol acyltransferase: Its regulation in vivo and some of properties in vitro. J Lipid Res 1980;21:930–941.
  30. Gillies PJ, Rathgeb KA, Robinson CS: Regulation of acyl-CoA:cholesterol acyltransferase activity in normal and atherosclerotic rabbit aortas: Role of a cholesterol substrate pool. Exp Mol Pathol 1986;44:320–339.
  31. Endo A: The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992;33:1569–1582.
  32. Fears R, Richards DH, Ferres H: The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks. Atherosclerosis 1980;35:439–449.
  33. Endo A, Tsujita Y, Kuroda M, et al: Effects of ML-236B on cholesterol metabolism in mice and rats: Lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta 1979;575:266–276.
  34. Ma PTS, Gil G, Sudhog TC, et al: Mevinolin, and inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 1986;83:8370–8374.
  35. Krause BR, Anderson M, Bisgaier CL, et al: In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rat is due to inhibition of both intestinal and liver ACAT. J Lipid Res 1993;34:279–294.
  36. Salisbury BG, Davis HR, Burrier RE, et al: Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption. SCH 48461. Atherosclerosis 1995;115:45–63.
  37. Van Heek M, France CF, Compton DS, et al: In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and Rhesus monkey through the identification of the active metabolites of SCH48461. Pharmacol Exp Ther 1997;283:157–163.
  38. Schnitzer-Polokoff R, Compton D, Boykow G, et al: Effects of acyl-CoA:cholesterol O-acyltransferase inhibition of cholesterol absorption and plasma lipoprotein composition in hamsters. Comp Biochem Physiol A 1991;99:665–670.
  39. Largis EF, Wang CH, DeVries VG, et al: CL 277082: A novel inhibitor of ACAT-catalysed cholesterol esterification and cholesterol absorption. J Lipid Res 1989;30:681–690.

    External Resources

  40. Williams RJ, McCarthy AD, Sutherland CD: Esterification and absorption of cholesterol: In vitro and in vivo observations in the rat. Biochim Biophys Acta 1989;1003:213–216.

    External Resources

  41. Marezetta CA, Savoy YE, Freeman AM, et al: Pharmacological properties of a novel ACAT inhibitor (CP-113,818) in cholesterol-fed rats, hamsters, rabbits, and monkeys. J Lipid Res 1994;35:1829–1838.
  42. Harris WS, Dujovne CA, von Bergmann K, et al: Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in humans. Clin Pharmacol Ther 1990;48:189–194.
  43. Bjorkhem I: Mechanism of bile acid biosynthesis in mammalian liver; in Danielson H, Sjovall J (eds): New Comprehensive Biochemistry. Amsterdam, Elsevier Scientific, 1985, pp 231–278.
  44. Field FJ, Cooper AD, Erickson SK: Regulation of rabbit intestinal acyl coenzyme A:cholesterol acyltransferase in vivo and in vitro. Gastroenterology 1982;83:873–880.

    External Resources

  45. Carr TP, Parks JS, Rudel LL: Hepatic ACAT activity in African green monkeys in highly correlated to plasma LDL cholesteryl enrichment and coronary artery atherosclerosis. Arterioscler Thromb 1992;12:1274–1283.
  46. Shand JH, West DW: The effects of simvastatin and cholestyramine, alone and in combination, on hepatic cholesterol metabolism in the male rat. Lipids 1995;30:917–926.
  47. Choi JS, Yokozawa T, Oura H: Antihyperlipidemic effect of flavonoids from Prunus davidiana. J Nat Prod 1991;54:218–224.